Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
United States
The Angeles Clinic and Research Institute (Melanoma), Los Angeles, California USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles, California Stanford Cancer Institute (Melanoma/NSCLC), Stanford, California Orlando Health Cancer Institute (Melanoma/NSCLC), Orlando, Florida James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville, Kentucky Memorial Sloan Kettering (Melanoma/NSCLC), New York, New York The Ohio State University, Columbus, Ohio Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh, Pennsylvania M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston, Texas